News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ipsen’s 2009 Results and Objectives
March 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Ipsen (Paris: IPN), chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
September 24, 2026
·
2 min read
·
Gabrielle Masson
Funding
Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs
September 24, 2026
·
1 min read
·
Tristan Manalac
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
